At the forefront of drug discovery targeting protein misfolding diseases At the forefront of drug discovery targeting protein misfolding diseases We are laser-focused on accelerating the development of first-in-class therapies for protein misfolding diseases, which represent a critical challenge in medical research due to their intricate mechanisms and the current lack of effective treatments. Target […]
Total raised: $130M
Investors 2
| Date | Name | Website |
| 18.12.2025 | Omega Fund... | omegafunds... |
| 25.12.2025 | Droia Onco... | droiaventu... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 01.12.2025 | Series B | $130M | - |
Mentions in press and media 3
| Date | Title | Description |
| 01.12.2025 | Protego Biopharma: $130 Million Series B Funding Closed To Advance Pivotal AL Amyloidosis Program | Protego Biopharma has closed an oversubscribed $130 million Series B financing round that will accelerate its first-in-class AL amyloidosis therapeutic program into a pivotal clinical study. The round was led by Novartis Venture Fund and Fo... |
| 01.12.2025 | Protego plans pivotal trial for AL amyloidosis prospect with $130M series B | Protego Biopharma is gearing up to bring its amyloid light-chain (AL) amyloidosis prospect into pivotal testing using its new $130 million series B fundraise. The oversubscribed funding round, led by Novartis Venture Fund and Forbion, picke... |
| 01.12.2025 | Protego Biopharma Raises $130M in Series B Financing | Brent Warner, CEO of Protego Biopharma Protego Biopharma, Inc., a San Diego, CA-based clinical-stage biotechnology company, closed a $130m Series B financing. The round was led by Novartis Venture Fund and Forbion, with participation from n... |